electroCore Announces First Quarter 2024 Financial Results
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
electroCore to Announce First Quarter March 31, 2024 Financial Results on Wednesday, May 8, 2024
Truvaga™ Plus Demonstrates Health Benefits in Latest Consumer Study, Paving the Way for Market Expansion
The science of nVNS
nVNS therapy stimulates the vagus nerve, which has been proven to help people suffering from a variety of disorders.
Pioneers of technology. Innovators of medicine.
We are pioneering the use of nVNS to deliver bioelectronic medicine for patient benefit.
Our Products. Our Passion.
Find innovative health and wellness solutions with electroCore's products, all utilizing our proprietary vagus nerve stimulation technology.
electroCore is committed to the safety and care of our patients, providers, and employees during the COVID-19 pandemic. We have implemented several operational enhancements, research initiatives, and virtual capabilities to ensure patients who depend on us have uninterrupted access to gammaCoreTM (non-invasive vagus nerve stimulator). To learn more about our efforts please call (888) 903-CORE.
By clicking “Accept” you are agreeing to eletroCore to place cookies on your browser to gather web statistics that help us improve our site experience. Please read our Privacy Policy for more information on the types of cookies we use.
